- Solid 7% sales growth in 2015 (€266m)
- Strong EBITDA growth with a 15% increase to €31m
Enhanced capabilities bring Novasep’s unique range of specialized drug development technologies within easier reach of North American customers
Strategic partnership creates a world leading CDMO offer to supply AAV-based viral vectors, an increasingly attractive therapeutic platform for gene therapy
Novasep’s BioSC® Lab continuous biochromatography equipment will enable CPI to disseminate next-generation downstream processes
Pierre-Louis Mikus joins as chief legal officer; Bertrand Waymel is promoted to group human resources director
- Swift execution of ‘Back to Basics’ strategic plan leading to successful portfolio reshaping
- All business units contributing to the strong performance
- 20% EBITDA growth driven by focus on attractive projects and cost control policy